[Asia Economy Reporter Park So-yeon] LabGenomics is showing strong performance in the early trading session.
On the 29th, as of 9:12 AM, LabGenomics is trading at 37,000 KRW on the KOSDAQ market, up 5,600 KRW (17.83%) from the previous trading day.
Founded in 2002, LabGenomics is a company engaged in in vitro diagnostic services and diagnostic product development. It was initially listed on the KONEX market and later transferred to the KOSDAQ market in 2014.
The company offers services such as 'CancerSCAN,' a cancer diagnostic test service based on its proprietary BI platform, and 'MomGuard,' the first NGS-based NIPT prenatal chromosomal abnormality test service in Korea.
Its consolidated subsidiaries include the biotechnology research company LabGenimics USA and the venture capital firm Lead Compass Investment.
Its market capitalization is 434.5 billion KRW, ranking 264th on the KOSDAQ.
Meanwhile, on the same day, Hanwha Investment & Securities maintained a buy rating on LabGenomics with a target price of 57,000 KRW, citing the emergence of the variant virus 'Omicron.'
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
